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Reporting of COVID-19 cases, deaths, and testing has often lacked context for appropriate 32 
assessment of disease burden within risk groups. The research considers how routine 33 
surveillance data might provide initial insights and identify risk factors, setting COVID-19 deaths 34 
early in the pandemic into context. This will facilitate the understanding of wider consequences 35 
of a pandemic from the earliest stage, reducing fear, aiding in accurately assessing disease 36 
burden and in ensuring appropriate disease mitigation. 37 
 38 
Setting 39 
United Kingdom, 2020.  40 
 41 
Participants 42 
The study is a secondary analysis of routine, public-domain, surveillance data and information 43 
from Office for National Statistics (ONS), NHS111 and Public Health England (PHE) on deaths and 44 
disease. 45 
 46 
Primary and secondary outcome measures 47 
Our principal focus is ONS data on deaths mentioning COVID-19 on the death certificate. We 48 
also consider information provided in NHS111 and PHE data summaries. 49 
 50 
Results 51 
Deaths with COVID-19 significantly contributed to, yet do not entirely explain, abnormally 52 
elevated all-cause mortality in the UK from weeks 12-18 of 2020. Early in the UK epidemic 53 
COVID-19 was the greatest threat to those with underlying illness, rarely endangering people 54 
aged under 40 years. COVID-19 related death rates differed by region, possibly reflecting 55 
underlying population structure. Risk of COVID-19-related death was greater for health and 56 
social care staff and BAME individuals, having allowed for documented risk factors.  57 
 58 
Conclusion 59 
Early contextualisation of public health data is critical to recognising who gets sick, when, and 60 
why. Understanding at-risk groups facilitates a targeted response considering indirect 61 
consequences of society’s reaction to a pandemic alongside disease-related impacts. COVID-19-62 
related deaths mainly mirror historical patterns, and excess non-COVID-19 related deaths partly 63 
reflect reduced access to and uptake of healthcare during lockdown. Future outbreak response 64 
 
 
will improve through better understanding of connectivity between disease monitoring systems 65 
to aid interpretation of disease risk patterns, facilitating nuanced mitigation measures.    66 
 67 
Article summary 68 
Strengths and limitations 69 
• The study shows how routine, public domain data can be used to provide pertinent 70 
insight into a pandemic in its earliest stages 71 
• The use of imaginative approaches to graphical display and numerical commentary 72 
ensures that the work can be understood by readers without a statistical specialism 73 
• This study uses a freely available statistics package to explore public domain data sets, 74 
ensuring that results are both transparent and repeatable 75 
• Insight is limited by problems in identifying raw data from some sources: improving ease 76 
of access will strengthen this process and improve the relevance of future inferences 77 
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INTRODUCTION  87 
Intense media reporting during the COVID-19 pandemic has focused on presenting daily data on 88 
cases, deaths and testing associated with the virus. The pandemic has undoubtedly changed our 89 
world - governments have employed unprecedented (in our times) lockdown methods to 90 
reduce transmission. These measures have greatly impacted society. The regular reporting of 91 
daily COVID-19 infections and deaths has alarmed the public, particularly when understanding 92 
of risk factors dictating severity of COVID-19 symptoms is only slowly emerging. The global 93 
population is immunologically naïve to this emerging pathogen, and society, at the time, had no 94 
available specific mitigation measures including immunological therapies, other than hand 95 
washing, social distancing, mask wearing and isolation when ill. Clinical and support staff in 96 
hospitals, health and social care staff in care homes and other settings, and key workers in 97 
transport and infrastructure industries were at increased risk of contracting the disease[1] due 98 
to frequent contact with people with high viral loads and the high aerosolised and fomite 99 
transmission potential of this virus[2]. Early analyses in England and Wales identified main risk 100 
factors for death from COVID-19 including older age, deprivation, and comorbidities[3], but did 101 
not consider how this risk differed from ‘typical’ all-cause mortality among these groups. This 102 
baseline comparison is vital to understanding what additional risk is posed by COVID-19, and to 103 
whom. Excess mortality from COVID-19 in the UK has been modelled, controlling for underlying 104 
conditions and age[4], and some conditions such as uncontrolled diabetes and severe asthma 105 
are associated with death[3]. However, understanding of the health loss impacts of COVID-19 is 106 
still limited by a lack of contextualising information, reducing our ability to respond to the 107 
challenges this disease poses, both directly and indirectly, in a proportionate, targeted manner. 108 
 109 
We provide context for deaths and disease from COVID-19, by comparing these against a 110 
historical benchmark of when, who, and how people become ill and died pre-COVID-19. 111 
Examining associations between poor COVID-19 outcomes, demographic and socio-economic 112 
differences, age, sex and comorbidities in the context of ‘usual’ population health structures, 113 
enhances understanding of specific risk groups and hence has a role to play in maximising the 114 
effectiveness of risk mitigation strategies whilst minimising the likelihood of unnecessary and 115 
undesirable impacts. Examining excess deaths (above that normally expected at a time-point) is, 116 
furthermore, important for interpreting the total impact of a pandemic. Syndromic surveillance 117 
describing clinical symptoms and healthcare use is scrutinised to supplement clinical 118 






Data sources  123 
The principal data source was the Office for National Statistics (ONS); dashboards from Public 124 
Health England (PHE) and syndromic surveillance in England via NHS 111 were additionally 125 
consulted. Primary focus for the analyses presented was the ONS data, which provide gold-126 
standard confirmed recorded causes of death for UK residents. Use of ONS data is licensed 127 
under the Open Government Licence v.3.0. 128 
 129 
Statistical methods  130 
All data must be viewed in their proper context before patterns can be inferred, and in this 131 
setting, against a historical baseline. In each case, profiles for COVID-19 deaths were considered 132 
against systematic differences in historical disease rates from appropriate comparison 133 
populations, to identify when disease was in excess of expected rates.  134 
 135 
Causes of death were defined using the International Classification of Diseases, 10th Revision 136 
(ICD-10)[5]. Deaths involving COVID-19 were defined as those with an underlying cause, or any 137 
mention, of ICD-10 codes U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not 138 
identified) on the death certificate. All causes of death is the total number of deaths registered 139 
during the same time period including those involving COVID-19.  140 
 141 
The baseline comparison group to examine weekly temporal variation in COVID-19 deaths was 142 
deaths from respiratory disease across a historical five-year period (2015 to 2019 inclusive). The 143 
mean number of respiratory deaths in weeks 1 to 16 of the year, together with an empirical 95% 144 
confidence interval, was calculated and plotted against the numbers of COVID deaths across this 145 
same time period in 2020.  146 
 147 
When considering data regionally, rates of death per million population was the primary focus: 148 
this allowed for different population sizes within regions and hence created a metric which is 149 
comparable across geographies. Here, the mean number of deaths per million population across 150 
the previous 5-year period was used as the baseline comparison. Deaths associated with COVID-151 
19 and excess deaths (deaths which do not attribute COVID-19 on the death certificate) were 152 




Rates were again used to compare the risks associated with different Standard Occupational 155 
Categories (SOCs) for individuals between 20 and 64 years of age. Age-standardised rates per 156 
100,000 population, standardised to the 2013 European Standard Population, were used in each 157 
category to correct for different numbers of people from different age groups working in each 158 
group, to ensure comparability between groups. Again the focus is upon the early part of the 159 
pandemic, with deaths registered up to and including 20th April 2020 constituting the data. 160 
Comparison with deaths from all causes occurring in these categories within the same 161 
timeframe creates a natural baseline for deciding how the rate of people dying with COVID-19 in 162 
a certain SOC compares with the rate of death in general in that SOC, and helps to distinguish 163 
specific COVID-related effects from more subtle societal impacts which might be influencing 164 
death rates more generally. Empirical 95% confidence intervals were provided to facilitate 165 
comparisons. 166 
 167 
To examine the effects in black and minority ethnic (BAME) groups, again early pandemic data 168 
from 2nd March to 10th April 2020 inclusive were considered. Odds ratios are used to compare 169 
categories; these were calculated by the ONS using logistic regression models which correct for 170 
age (in 5 year categories); rural or urban inhabitants; IMD decile; socio-economic status; and 171 
self-reported health and activity status. Forest plots were used to show the estimated odds 172 
ratios for dying in each category; 95% confidence intervals were also represented. 173 
 174 
Finally, the representation of co-morbidities amongst COVID-19 deaths in March and April 2020 175 
was explored graphically using a stacked bar chart of the proportion of males and females 176 
separately reporting each co-morbidity across age categories (including 0-44 years; 45 to 49 177 
years; 50 to 54 years; 55 to 59 years; 60 to 64 years; 65 to 69 years; 70 to 74 years; 75 to 79 178 
years; 80 to 84 years; 85 to 89 years; and 90 years plus). This allows immediate comparison of 179 
how the profile of co-morbidities changes in general by age; whether different comorbidities are 180 
more readily apparent in males and females; and whether the evolution of comorbidities as age 181 
increases, differs for the two sexes.  182 
 183 
All statistical analyses were conducted in Microsoft Excel and the R statistical software package 184 






Temporal variation in COVID-19 deaths  189 
The number of deaths from all causes varies annually and seasonally, peaking in winter. 190 
Typically, respiratory deaths range from 10% to 22% of all deaths and are seasonal, peaking 191 
annually in January; the 2015 peak was high (16,237 deaths in week two compared to an 192 
average of 12,277 deaths that week over the previous five years) due to a severe influenza 193 
season, and 2018 similarly had a severe influenza season resulting in a high death count. The 194 
minimum number of weekly deaths over this five year period was 6,606 (week 54, 2013). In 195 
2020 deaths from respiratory infections were lower than the mean in the previous five years 196 
until early April (week 14), after which they became higher than historical rates when including 197 
deaths from COVID-19 (Figure 1a) (in week 14 observed respiratory deaths exceeded the 5-year 198 
historical upper 95% confidence interval limit by 146). An excess of unexplained deaths 199 
becomes clear from week 14 onwards (Figure 1b). Following a period of excess deaths, in week 200 
25 of 2020, for the first time there were fewer deaths than the equivalent previous 5 year 201 
average (65 fewer deaths), and similarly in weeks 26 through to 28 there were 917 fewer deaths 202 
than the total of the averages across years for those weeks in the previous five years[8]. 203 
 204 
FIGURE 1a AND 1b HERE 205 
 206 
Regional differences in COVID-19 deaths 207 
Regions of England and Wales experience different death rates and this pattern is true for 208 
deaths from COVID-19 (Figure 2) e.g. rates were highest and peaked in week 17 in London (204 209 
per million), the North-West (185 per million), the North-East (179 per million), and the West 210 
Midlands (169 per million). Peak rates were lowest in the South-West (95 per million) and East 211 
Midlands (116 per million). From weeks 13-18 (March 23-May 3), all regions of England and 212 
Wales experienced excess non-COVID-19 related deaths. This was most apparent in the West 213 
Midlands in week 17 (starting April 20), with a peak of approximately 91 deaths per million. 214 
Between weeks 13-18 (March 23- May 3) there were 46,594 excess deaths in England and 215 
Wales, 13,399 of which were listed as non-COVID-19-related. In week 25 (19th June) the total 216 
deaths dipped below the 5-year historical average for the first time (9,339 compared to 9,404) 217 
and this pattern continued until 10th July. 218 
 219 




Occupational differences in COVID-19 deaths  222 
After age-standardisation (rates per 100,000 population, standardised to the 2013 European 223 
Standard Population), men employed in lower skilled occupations (21.4, 95% CI 18.6-24.2) 224 
(Figure 3a) were more likely to die of COVID-related illness (k=225 deaths from n=1321 deaths 225 
in total across occupations for men[9]), as was true for all-cause mortality (Figure 3b, k=915 226 
deaths out of n=5627 deaths). This differs for women, where those employed as carers in health 227 
and social care, leisure and other service operations (Figure 3a) were most likely to die from 228 
COVID-related illness (k=130 deaths out of n=531 deaths in total across occupations for 229 
women), but not more likely to die if examining all-cause mortality (Figure 3b, k=651 deaths 230 
from n=3003 deaths). For both men and women, the less technical and more manual their 231 
occupation (using ONS SOC 2020 categories), the greater the risk of dying from any cause 232 
including COVID-19-related disease. In addition, when occupations are more manual, variation 233 
in age-standardised mortality rates is higher, particularly for men or women in certain SOC 234 
categories e.g. men undertaking administrative and secretarial roles; women in skilled trades; 235 
men in caring, leisure and other service occupations; men in sales and customer service roles; 236 
women working as process, plant and machine operatives; and men undertaking low skilled 237 
elementary roles.  238 
 239 
FIGURE 3a AND 3b HERE. 240 
 241 
A crude comparison suggests that age-standardised mortality rates for most occupations are 242 
reduced by COVID-19 relative to deaths from any cause (Table 1), with the rate only increased 243 
(for both sexes) in caring, leisure and other service occupations. 244 
 245 
Table 1: Ratio of estimated age-standardised mortality rates comparing occupational 246 
categories with a baseline of managerial workers (SOC group 1) for (a) COVID-19 associated 247 
male and female deaths; and (b) all-cause male and female deaths (including COVID-19). Note 248 
caution must be exercised in interpreting the values in Table 1 as they do not contain 249 





COVID All COVID All 
 
 
1 Managers, directors and senior officials (baseline) - - - - 
2 Professional occupations 1.05 1.02 0.67 0.72 
3 Associate professional & technical occupations 0.85 0.87 0.89 1.07 
4 Administrative & secretarial occupations 0.95 1.14 1.65 1.61 
5 Skilled trades occupations 1.60 2.06 1.39 2.18 
6 Caring, leisure & other service occupations 1.88 1.77 2.13 1.98 
7 Sales & customer service occupations 1.35 1.37 1.70 1.49 
8 Process, plant & machine operatives 1.43 2.36 1.85 1.97 
9 Low skilled elementary occupations 1.53 1.66 2.55 2.77 
 253 
 254 
Ethnic associations with COVID-19 deaths  255 
As previously reported by the ONS[10] in data from 2nd March to 10th April 2020, there were 256 
increased odds of dying from COVID-19 for Bangladeshi/Pakistani (386 deaths), Black (766 257 
deaths) and Indian (483 deaths) ethnic groups (for both sexes) when compared with a baseline 258 
white group and adjusted for age, region, rural/urban, Index of Multiple Deprivation decile, 259 
household composition, socio-economic status and underlying health Conditions (Figure 4a and 260 
4b). In total across all groups, in this time period 12,805 deaths occurred. For Chinese and mixed 261 
ethnic groups the odds ratio was not statistically significantly different from one, perhaps due to 262 
small sample size (59 deaths in total observed in Chinese ethnic groups in this time period, from 263 
a total of 12,805 across all categories).  264 
 265 
FIGURE 4a AND 4b HERE. 266 
 267 
Impact of comorbidities upon COVID-19 deaths  268 
Deaths related to COVID-19 reflect broad underlying patterns, with more reported in men 269 
(61.3%, n=6,342) and older people (at week 15, 87% (n=8,985) of deaths were in those aged 270 
over 65, 69% (n=7,135) were in people aged over 75). Data from the ONS across 2019 show an 271 
increased proportion of health conditions (chest and breathing issues and heart/blood 272 
pressure/circulatory problems) related to age. The percentages of people with heart, blood 273 
pressure, or circulatory problems were 0.48% (16-19 years); 6.31% (20-39 years); 31.35% (40-59 274 
years); and 61.86% (60+ years). Similarly, the percentages of people with chest and breathing 275 
problems were 4.85% (16-19 years); 26.96% (20-39 years); 32.23% (40-59 years); and 35.96% 276 
(60+ years)[11]. Long-term comorbidities such as ischaemic heart disease and hypertensive 277 
disease are commonly present in men dying with COVID-19 (Figure 5a), particularly in higher 278 
age groups; a similar pattern was observed for cerebrovascular diseases in women (Figure 5b). 279 
 
 
As people reach very advanced age, for both sexes the predominant comorbidities are dementia 280 
and Alzheimer’s (Figures 5a and 5b).  281 
 282 
FIGURE 5a AND 5b HERE. 283 
 284 
Impacts of our response to COVID-19 285 
Numerous other resources can provide information about the impacts of the human response 286 
to the pandemic. The response to COVID-19 appears to indirectly increase non-COVID-19 287 
mortality by reducing healthcare-seeking behaviour: a big reduction in the number of visits to 288 
accident and emergency units (from 120,356 in the week commencing 16th March to 89,584 in 289 
the week commencing 23rd March)[12,13] coincides with the increase of both COVID-19 and 290 
non-COVID-19-related UK deaths. There are wide impacts on a range of non-communicable 291 
diseases: for example, Cancer Research UK have estimated that for every week that routine 292 
screening is paused, 7,000 people miss referrals for further tests, and 380 cancers are not 293 
diagnosed using routine screening programmes[14]: they additionally estimate that 290,000 294 
people fewer than usual have been referred for further tests.  295 
 296 
Data suggests that routine preventive screenings, cancer treatments, dental visits, and 297 
vaccinations have all been paused to some extent during the lockdown. Evidence for this is 298 
provided in a report to the NHS by Medefer, reported in the Times (10th May 2020). It suggests 299 
that by October 2020, approximately 7.2 million people will be on NHS waiting lists. The report 300 
estimates that 1.3 million people may already have been added to a lengthy waiting list which 301 




This analysis characterises the COVID-19 pandemic in England and Wales in the context of 306 
excess death over time, by region, and risk factor. Increases in mortality in April were 307 
predominantly driven by COVID-19, but non-COVID-19 excess deaths also increased in April-May 308 
2020 across all regions. Compared to historical rates of death amongst occupational groups, 309 
COVID-19 related deaths generally followed normal patterns, excepting individuals among 310 
caring, leisure, and other service occupations who were more likely to die from COVID-related 311 
illness than die from any illness. Rates of death from COVID-19 related illness are higher among 312 
Black and Ethnic Minority (BAME) populations, but small sample sizes preclude all-cause 313 
 
 
mortality comparisons. Finally, pre-existing comorbidities are a strong risk factor for COVID-19 314 
related death and are more common among men and the elderly, explaining why these groups 315 
appear to be at excess risk of death related to COVID-19. Thus, patterns of death and excess 316 
death from COVID-19 mirror historical trends in mortality. This contextualisation of COVID-19 is 317 
critical to inform plans to protect the vulnerable while helping low risk populations in society to 318 
resume more normal lifestyle patterns. 319 
 320 
The lower-than-expected death toll from week 25 onwards may be suggestive of a mortality 321 
displacement (‘harvesting’) impact; a proportion of the population who died at the epidemic 322 
peak (weeks 13 to 18) may have died in the shorter-term in other circumstances. The complete 323 
picture is likely to be far more complex, but the harvesting phenomenon is previously described 324 
e.g. due to impacts of heatwaves and cold spells[15] and influenza in 1918/19 (compared to 325 
deaths from tuberculosis)[16]. Such population readjustments need to be taken into account in 326 
planning processes as the overall health loss may be relatively small compared to a disease or 327 
health problem that kills people who are healthy. 328 
Context to age and gender 329 
Much age and gender-related health risk is more appropriately attributable to increased 330 
prevalence of underlying comorbidities. We are more likely to die as we age, with 84% of annual 331 
deaths in people over 65 years, and 66% in those over 75 years[17]. Men also die earlier in most 332 
age groups and have lower life expectancies (79.2 years) than women (82.9 years)[18]. As we 333 
age our likelihood of having long-term illness increases as has been discussed. Though the 334 
burden of risk from COVID-19 lies with older age groups, more thorough epidemiological 335 
analysis may identify some subpopulations that could be classified as lower (or higher) risk. Such 336 
analysis would inform better risk management strategies, allowing mobility and economic 337 
activity amongst some low-risk older populations, as well as intrinsically low risk groups such as 338 
young people.  339 
Context to comorbidities 340 
Patterns of co-morbidities for COVID-19-related deaths mirror the increase in these diseases 341 
with age (in non-COVID circumstances) e.g. ischaemic heart disease is more frequently 342 
experienced with age by men than women[19]. It is unclear whether an increasing 343 
representation of dementia and Alzheimer’s as comorbidities is seen because they are genuine 344 
comorbidities in their own right or due to data biases. The most important other comorbidities 345 
are chronic lower respiratory disease in females and ischaemic heart disease in males. A role for 346 
 
 
specific genes linked to dementia and Alzheimer’s and poor COVID-19 response has recently 347 
been suggested[20] and warrants further investigation. It has not been possible to locate for 348 
2020, the numbers of deaths by each comorbidity in its own right: these would be useful for 349 
comparison and establishment of any excess, but whether an excess of deaths with COVID-19 by 350 
any of the comorbidities will occur is unclear at the time of writing. 351 
Context to ethnicity and occupation 352 
Ethnicity and occupation are common risk factors for morbidity and mortality from infectious 353 
disease, but are not often reported in surveillance data[21]. Heightened reported risks among 354 
specific ethnic and occupational groups are alarming, and COVID-19 has brought renewed 355 
attention to health disparities inherent in the UK population, but excepting care, service, and 356 
leisure workers, the precise nature and drivers of excess COVID-19 risk in different groups 357 
remains unclear. When considering occupational risk for example, age-standardised mortality 358 
ratios (ASMRs) in different occupational categories for COVID-19 mortality must be considered 359 
alongside ASMRs for all-cause mortality. For example, when the COVID-19-associated ASMR in 360 
an occupational category is high relative to deaths from all causes, this suggests COVID-19-361 
associated impacts should be considered in managing return to work.  362 
Consequences of COVID-19 and our response to its presence 363 
The reduction in accident and emergency consultations is inconsistent with the pattern 364 
observed in 2019; it suggests a reluctance or inability of the public to access healthcare during 365 
lockdown. Unfortunately, comparisons against a longer range of historical data are not possible 366 
since the surveillance system changed in 2018, with greater numbers of hospitals reporting to 367 
the system from this point onwards. The reasons for this reduction may be multi-factorial 368 
reflecting reluctance, fear of the virus, and logistical difficulties for GPs. This pattern of reduced 369 
healthcare uptake foreshadows an increased health burden as a result of the combination of 370 
delays introduced into the system by aspects of both the health services and individuals’ 371 
responses to COVID-19. However, in the immediate future, a dip in mortality is occurring, 372 
compared to baseline. In Wales, where the median age is higher than in any other UK nation or 373 
region of England[22], the rate of death per million returned to at, or below, historical levels 374 
before any other region in England. This suggests that for high-risk populations (e.g. the elderly), 375 
deaths have been compressed within the time window of the pandemic. This phenomenon was 376 
previously observed among tuberculosis patients in the months and years following the 1918 377 
Spanish Flu[16]. Thus, continued contextualisation of deaths is critical to accurately assess the 378 
 
 
long-term impact of COVID-19 on health in the UK - volatility of demand should be considered in 379 
resource planning. 380 
Solutions: Role of surveillance, need for better data reporting 381 
What tools do we have to look at whether changes in illness patterns might be helpful in 382 
planning a response to an emerging situation such as COVID-19? ONS data are among the most 383 
accurate but have limited usefulness for real-time analysis. It is crucial that information from 384 
multiple sources is synthesised and scrutinised simultaneously, balancing timeliness against 385 
accuracy. Many readily available sources can be used in combination to inform the evidence-386 
base. In other illnesses such as influenza[23], a primary circulation in children may precede a 387 
secondary epidemic in the wider population. Of relevance to COVID-19 is syndromic surveillance 388 
reporting, which illustrated a spike in consultations for influenza-like illness in the under 15s 389 
above baseline for weeks 49 to 51 of 2019[24]. This, considered in tandem with other syndromic 390 
surveillance data, which indicated increased trips for influenza-like illness to accident and 391 
emergency in the same period[12], have the potential to alert society to anomalies earlier than 392 
the documented timescale for the COVID-19 pandemic. Combined scrutiny of such sources is 393 
useful to identify anomalous patterns, triggering a public health response. For example, 394 
coincident with the first reported case of COVID-19 in the UK, calls reporting cough or cold/flu 395 
and diarrhea spiked, then fell when the NHS 111 changed their call triage system[24]. Ensuring 396 
the comparability of age categories across reporting systems, and reporting data openly at the 397 
highest resolution which respects patient anonymity, aids rapid responsive production of 398 
understanding from research. On the international stage, authors in the US have identified 399 
analogous issues with non-integrated reporting systems; they developed an ‘App’ that attempts 400 
to address some of the issues[25]. In Europe, two surveillance strands are followed and both are 401 
restricted access: EU/EEA Member States and the UK report for every 24 hour period the 402 
number of laboratory-confirmed cases of COVID-19 using their Early Warning and Response 403 
System (EWRS). Enhanced surveillance has also been put in place via The European Surveillance 404 
System – TESSy[26]. The restricted access nature of these resources limits their real-time 405 
applicability for parties other than those with permitted access. A full consideration of the 406 
international picture is beyond the scope of this paper, but the process described herein could 407 
be repeated for other populations. 408 
Solutions: A model for success 409 
Taiwan provides perhaps the best example of success in rapidly containing and controlling 410 
COVID-19; they eliminated the virus by April 2020 without going into lockdown, with minimal 411 
 
 
economic damage and few deaths[27]. Taiwan’s plan for success against COVID-19 can be 412 
summarised in four points[28]. 1) In response to previous experience with SARS in 2003 and 413 
influenza H1N1 in 2009, Taiwan had developed highly functional pandemic response plans and 414 
infrastructure that were immediately operationalised in early 2019, including a Central Epidemic 415 
Command Centre and community surveillance system. 2) Taiwanese officials were quick to 416 
respond to the earliest whistle-blower reports from China with significant travel restrictions and 417 
activation of pandemic response plans. 3) The Taiwanese government is trusted and was able to 418 
successfully balance government oversight with regional autonomy. Localities and private 419 
establishments were trusted to run their own track and trace systems, which were designed to 420 
be easily linked up to provide national coverage. Privacy concerns are acknowledged and 421 
managed, but the proven results obtained drive high levels of participation. 4) High buy-in from 422 
civilians across all aspects of disease control. Civilians are given space to provide suggestions 423 
and concerns in online town-halls. Civilians are provided with adequate monetary support while 424 
quarantining, but also face large fines, leading to high compliance. While there are cultural, 425 
social, and geographic differences between the UK and Taiwan, many of these actions could be 426 
successfully deployed in the UK.  427 
 428 
CDC specify a series of steps to be followed in investigating and responding to an outbreak 429 
Figure 6 outlines where this research contributes to that process, and how it feeds into the 430 
wider process of outbreak management. It is clear from this figure how timely data from a 431 
variety of sources, at closely aligned degrees of temporal and spatial resolution, would 432 
streamline public health processes, significantly enhancing capacity to respond to future 433 
pandemics.  434 
 435 
FIGURE 6 HERE. 436 
 437 
Methodological limitations 438 
Any analysis based upon surveillance data is subject to limitations. Biases in surveillance data 439 
are well-known and well-documented[29]. Data on cases of disease is informative but can be 440 
heavily biased by who appears in the system, and why. For example, any estimate of the case 441 
fatality ratio for COVID-19 from the early part of the pandemic would potentially be over-442 
estimated as a consequence of the likely huge under-ascertainment of disease in the early 443 
stages, when knowledge about COVID-19 was evolving, and testing was largely limited to 444 
hospital cases of disease (the most severe manifestations). It is for this reason that the research 445 
 
 
in this paper has focused on data from the ONS, which records conclusive cause of death and is 446 
the most complete and accurate resource for UK deaths which should ensure that any biases of 447 
reporting are minimised. 448 
 449 
The analysis presented here is largely descriptive, and as such it is not possible to make any 450 
statements about, for example, statistical significance of observations. This approach is 451 
deliberate: it is the authors’ intention to demonstrate how a well-chosen graphical display can 452 
provide valuable insight, which can be readily interpreted by those without specialist 453 
knowledge.  454 
Conclusions 455 
 456 
Policy makers have relied on models in the early phase of COVID-19. These must be supported 457 
by data-driven evidence on when, where, who and why people get sick and die. Timely 458 
emergence and analysis of this information should be used to calibrate social, cultural and 459 
economic assessments of the impact of COVID-19 versus our actions to control it, if we are to 460 
return to a cautious normality. 461 
 462 
To our knowledge this is the first study to consider reported numbers of COVID-19 illnesses and 463 
deaths in England and Wales against their historical disease context. Our research identifies and 464 
combines important, open-access data to inform a more nuanced response to emerging 465 
disease. Many openly available resources could improve response planning for emerging 466 
disease situations such as COVID-19, and could be used to anticipate wider consequences than 467 
immediate infection-related impacts. Syndromic surveillance data combined with real-time 468 
surveillance would supplement and strengthen the mathematical models informing emerging 469 
disease responses. Our analysis highlights the importance of calibrating social, cultural and 470 
economic assessments of the direct impact of COVID-19 against potential control actions.  471 
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Figure captions 592 
Figure 1: Time series plots representing (a) Number of respiratory deaths per week in the 
first 16 weeks of 2020, by comparison with a temporally equivalent 5 year historic 
baseline mean (with 95% confidence intervals); and (b) Number of deaths; respiratory 
deaths; deaths with COVID-19 on the death certificate; and deaths without COVID-19 on 
the death certificate, across the first 16 weeks of 2020. 
 
Figure 2: All-cause and COVID-19 deaths by region between weeks 12 and 20 of 2020. 
 
Figure 3: Age-standardised mortality rate by Standard Occupational Category (SOC) for (a) 
deaths mentioning COVID-19 on the death certificate and (b) all deaths registered up to 
and including 20th April 2020. 
 
Figure 4: Odds ratios by ethnic category for deaths between 2nd March to 10th April 2020 
which mention COVID-19 on the death certificate. 
 
Figure 5: Stacked barplot representing the main comorbidities for COVID-19 by age, for 
deaths occurring in March and April 2020. CerebVasc = cerebrovascular disease; ChrLRD = 
Chronic lower respiratory disease; CirrLD; Dem&Alt; Diabetes; DisUrS = Disease of the 
urinary system; Flu&pneu = Influenza and pneumona ; HeartF = Heart failure; Hypert = 
Hypertension; IschHD = Ischaemic heart disease; MaNPbreast = malignant neoplasm of 
the breast; MalNPlowDigest = malignant neoplasm of the lower digestive tract; 
 
 
MalNPLymph = malignant neoplasm of the lymphatic system; MalNPresp malignant 
neoplasm of the respiratory system; MaNPprost malignant neoplasm of the prostate; 
Nopreext no pre-existing condition; Obesity; OtherDegen = Other degenerative disease; 
Park = Parkinson’s disease; Pulm = Pulmonary disease; SymptIll = Ill-defined symptoms. 
 
Figure 6: Schematic describing the role of data, analysis and information generation in an 
iterative approach to pandemic management and infectious disease public health. 
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